Iguratimod is an anti-inflammatory drug for the treatment of rheumatoid arthritis. It is approved for use in China and Japan and is sold by Eisai and Toyama Chemical. Its mechanism of action involves the suppression of nuclear factor-kappa B (NF-κB).
This page contains content from the copyrighted Wikipedia article "Iguratimod"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
